(Q37634106)

21 August 2017

1 reference

title

The role of anti-core antibody response in the detection of occult hepatitis B virus infection (English)

1 reference

21 August 2017

1 reference

1 reference

1 reference

4

Massimo Franchini

1 reference

21 August 2017

Simona Urbani

1

1 reference

21 August 2017

Francesco Fagnoni

series ordinal

2

1 reference

21 August 2017

Gabriele Missale

series ordinal

3

1 reference

21 August 2017

publication date

1 January 2010

1 reference

Clinical Chemistry and Laboratory Medicine

21 August 2017

published in

1 reference

21 August 2017

volume

48

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

23-29

1 reference

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatitis B virus infection--natural history and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatocellular carcinoma and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

HBV induced carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Occult hepatitis B virus infection: a hidden menace?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Statements from the Taormina expert meeting on occult hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Reactivation of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Occult hepatitis B virus infection: implications in transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

The high-risk donor: viral infections in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatitis B virus transmission in organ, tissue, and cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Clinical impact of occult HBV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Kinetics of the immune response during HBV and HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

"Occult" hepatitis B virus as source of infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Review article: hepatitis B and liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Use of hepatitis B core antibody-positive donors for liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Natural history of chronic hepatitis B in co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Post-transfusion hepatitis type B following multiple transfusions of HBsAg-negative blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Serologic diagnosis of acute and chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

The humoral immune response in acute and chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatitis B virus markers in anti-HBc only positive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Italian blood donors with anti-HBc and occult hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Serologic and molecular profile of anti-HBc-positive blood bank donors in an area of low endemicity for HBV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatitis B virus blood screening: unfinished agendas

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatitis B virus infection and transfusion medicine: science and the occult

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Occult hepatitis B virus in liver tissue of individuals without hepatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Hepatitis B virus (HBV) screening strategy to ensure the safety of blood for transfusion through a combination of immunological testing and nucleic acid amplification testing - Japanese experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Occult hepatitis B virus infection in a North American community-based population

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

Occult hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.002

21 January 2018

Identifiers

DOI

10.1515/CCLM.2010.002

1 reference

21 August 2017

1 reference